Latest Insider Transactions at Gossamer Bio, Inc. (GOSS)
This section provides a real-time view of insider transactions for Gossamer Bio, Inc. (GOSS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Gossamer Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Gossamer Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2022
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,278
-2.88%
|
$50,224
$8.28 P/Share
|
|
Mar 16
2022
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
6,279
-8.67%
|
$50,232
$8.28 P/Share
|
|
Mar 16
2022
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,002
-5.25%
|
$40,016
$8.28 P/Share
|
|
Oct 25
2021
|
Richard Aranda Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,377
-1.08%
|
$28,524
$12.25 P/Share
|
|
Oct 25
2021
|
Laura Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,377
-2.43%
|
$28,524
$12.25 P/Share
|
|
Oct 25
2021
|
Caryn Peterson EVP, Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
2,377
-3.18%
|
$28,524
$12.25 P/Share
|
|
Jun 30
2021
|
Laura Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.38%
|
-
|
|
Jun 21
2021
|
Richard Aranda Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+6.39%
|
-
|
|
May 03
2021
|
Laura Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,820
+12.96%
|
-
|
|
Apr 16
2021
|
Caryn Peterson EVP, Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
10,820
+12.63%
|
-
|
|
Mar 23
2021
|
Waage Christian EVP, Tech Ops and Admin |
SELL
Open market or private sale
|
Direct |
5,490
-0.92%
|
$49,410
$9.48 P/Share
|
|
Mar 23
2021
|
Bryan Giraudo COO/CFO |
SELL
Open market or private sale
|
Direct |
5,490
-4.76%
|
$49,410
$9.48 P/Share
|
|
Mar 23
2021
|
Luisa Salter Cid Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,491
-2.6%
|
$49,419
$9.48 P/Share
|
|
Feb 25
2021
|
Waage Christian EVP, Tech Ops and Admin |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+7.05%
|
-
|
|
Feb 25
2021
|
Bryan Giraudo COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+28.06%
|
-
|
|
Feb 25
2021
|
Luisa Salter Cid Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+17.54%
|
-
|
|
Feb 25
2021
|
Faheem Hasnain President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
162,500
+50.0%
|
-
|
|
Oct 14
2020
|
Bryan Giraudo COO/CFO |
BUY
Open market or private purchase
|
Indirect |
3,000
+29.64%
|
$30,000
$10.01 P/Share
|
|
Oct 14
2020
|
Faheem Hasnain President & CEO |
BUY
Open market or private purchase
|
Indirect |
96,520
+2.7%
|
$965,200
$10.36 P/Share
|
|
Oct 14
2020
|
Waage Christian EVP, Tech Ops and Admin |
BUY
Open market or private purchase
|
Indirect |
2,500
+26.44%
|
$22,500
$9.53 P/Share
|